title: Statin use and risk of glioma: population-based case-control analysis.
abstract: Statins have been reported to decrease the incidence of cancer, but the risk of glioma among statin users has been investigated in only two prior observational studies, both of them suggesting a modest protective effect of statins. We conducted a matched case-control study using data from the UK-based Clinical Practice Research Datalink to analyse use of statins among 2469 cases with glioma and 24,690 controls. We performed conditional logistic regression analysis to calculate relative risks, estimated as odds ratios (ORs) with 95 % confidence intervals (CIs) adjusting for multiple confounding factors. As compared with non-use of statins, use of statins was not associated with risk of glioma (OR for ≥90 prescriptions=0.75; 95 % CI 0.48-1.17). Our findings do not support previous sparse evidence of a possible inverse association between statin use and glioma risk.
authors.affiliation: Department of Neurology and Wilhelm Sander-NeuroOncology Unit, Regensburg University Hospital, Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Germany. corinna.seliger@klinik.uni-regensburg.de.
authors.forename: Corinna
authors.initials: C
authors.lastname: Seliger
authors.affiliation: Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Spitalstrasse 26, 4031, Basel, Switzerland.|Boston Collaborative Drug Surveillance Program, Boston University School of Public Health, 715 Albany St., Boston, MA, 02118, USA.|Hospital Pharmacy, University Hospital Basel, Spitalstrasse 26, 4031, Basel, Switzerland.
authors.forename: Christoph Rudolf
authors.initials: CR
authors.lastname: Meier
authors.affiliation: Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Spitalstrasse 26, 4031, Basel, Switzerland.
authors.forename: Claudia
authors.initials: C
authors.lastname: Becker
authors.affiliation: Boston Collaborative Drug Surveillance Program, Boston University School of Public Health, 715 Albany St., Boston, MA, 02118, USA.
authors.forename: Susan Sara
authors.initials: SS
authors.lastname: Jick
authors.affiliation: Department of Neurology and Wilhelm Sander-NeuroOncology Unit, Regensburg University Hospital, Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Germany.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Bogdahn
authors.affiliation: Department of Neurology and Wilhelm Sander-NeuroOncology Unit, Regensburg University Hospital, Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Hau
authors.affiliation: Department of Epidemiology and Preventive Medicine, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Germany.
authors.forename: Michael Fred
authors.initials: MF
authors.lastname: Leitzmann
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D005910:Glioma / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Case–control study; Epidemiology; Glioma; Statins